Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: A review

Liver International

Volumn 29, Issue SUPPL. 1, 2009, Pages 31-38

  Tarantino, Giuseppe ^a   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Chronic hepatitis C; Genotype 2 and 3; Short therapy

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG RESPONSE; DRUG SAFETY; FATTY LIVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW DRUG DOSE; MONOTHERAPY; PREDICTION; RELAPSE; TREATMENT DURATION; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; RIBAVIRIN;

EID: 59149091938     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01924.x     Document Type: Conference Paper

References (25)

1. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358: 958-65.
2. Fried MW, Schiffman L, Reddy KR., et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
3. Hadziyannis SJ, Sette Jr H, PEGASYS International Study Group, et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
4. American Gastroenterological Association. Technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-64.
5. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-9.
6. Dalgard O, Bjøro K, Block Hellum K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology 2004; 40: 1260-5.
7. Mangia A., Santoro R, Minerva N, et al. Peginterferon alpha-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.
8. Von Wagner M, Huber M, Berg T, et al. Peginterferon alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-27.
9. Shiffman M, Suter F, for the ACCELERATE Investigators, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3. N Engl J Med 2007; 357: 124-34.
10. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5: 124-9.
11. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-9.
12. Dalgard O, Bjøro K, the North-C Group, et al. Pegylated interferon alpha and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 35-43.
13. Lagging M, Langeland N, NORDynamIC Study Group, et al. Nordynamic trial. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47: 1837-45.
14. Mangia A, Minerva N, Bacca D, et al. Factors predictive of relapse in genotype 2 and 3 patients treated for 12 weeks with PEGIFN alpha 2b and weight based ribavirin combination [abstract]. J Hepatol 2008; 48(Suppl. 2): S6 (Abstract 8).
15. Willems B, Hadziyannis SJ, Morgan TR, et al. Should treatment with peginterferon plus ribavirin be intensified in patients with HCV genotype 2/3 without a rapid virological response? [abstract]. J Hepatol 2007; (Suppl. 2): S6 (Abstract 8).
16. Ferenci P, Brunner H, for the Austrian Hepatitis Study Group, et al. A randomized, prospective trial of ribavirin 400mg/day versus 800mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008; 47: 1816-23.
17. Christensen PB, Alsio AA, Buhl MR, et al. Ribavirin concentration at week four is an independent predictor for sustained virological response after treatment of hepatitis genotype 2/3 (Nordynamic trial) [abstract]. J Hepatol 2008; 48(Suppl. 2): S6 (Abstract 10).
18. Bruno S, Maisonneuve P, Pockros PJ, et al. Efficacy and safety of peginterferon alfa-2a (40 KD) plus ribavirin in HCV patients with complete cirrhosis (Knodell score F4) [abstract]. Hepatology 2006; 44(Suppl. 1): 332A, (Abstract 380).
19. Bruno S, Hadziayannis SJ, Shiffman ML, Messinger D, Marcellin P. Base-line and on treatment factors associated with high rates of sustained virological response in patients with or without cirrhosis following treatment with peg-interferon alpha-2a and ribavirin [abstract]. J Hepatol 2008; 48(Suppl. 2): S289 (Abstract 774).
20. Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: A randomized controlled trial. J Hepatol 2007; 47: 484-91.
21. Coverdale SA, Khan MH, Byth K, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow up study. Am J Gastroenterol 2004; 99: 636-44.
22. Ferenci P, Bergolz U, Laferl H, et al. Is shorter treatment with peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) possible in HCV genotype 1 'super-responders'? Preliminary results of a prospective randomized clinical trial [abstract]. Hepatology 2005; 42(Suppl. 1): 218 (Abstract 56).
23. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.
24. Jensen D, Morgan T, Marcellin P, et al. Rapid virological response at week 4 (RVR) of peginterferon alfa-2a (Abstract 40KD) (Pegasys®) plus ribavirin (RBV, Copegus ®) treatment predicts sustained virological response (SVR) after 24 weeks in genotype 1 patients [abstract]. Hepatology 2005; 42(Suppl. 1): 650A (1155).
25. Shiffman M, Nelson D, Zeuzem S. Rapid virologic response (RVR) in combination with baseline viral load is highly predictive of sustained virologic response (SVR) in HCV genotype 2/3 (G2/3) patients treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) (abstract). Hepatology International 2008; 2(Suppl.): S229 (Abstract 23).